Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Novartis Pharmaceuticals
Paul M Ridker; Jean G MacFadyen; Tom Thuren; Brendan M Everett; Peter Libby; Robert J Glynn